SEC Form 10-Q filed by Sorrento Therapeutics Inc.
$SRNE
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $5.00 | Overweight | Cantor Fitzgerald |
| 8/9/2021 | $30.00 → $26.00 | Buy | HC Wainwright & Co. |
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
5 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023. The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case. A hearing for final approval of
SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a
SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a
SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed
Gainers TransMedics Group (NASDAQ:TMDX) stock moved upwards by 10.2% to $71.15 during Wednesday's after-market session. The market value of their outstanding shares is at $2.2 billion. As per the news, the Q4 earnings report came out today. AquaBounty Technologies (NASDAQ:AQB) shares rose 6.32% to $0.84. The company's market cap stands at $59.7 million. BioVie (NASDAQ:BIVI) stock increased by 5.83% to $5.99. The market value of their outstanding shares is at $209.5 million. Infinity Pharmaceuticals (NASDAQ:INFI) stock moved upwards by 5.45% to $0.58. The company's market cap stands at $51.8 million. Tivic Health Systems (NASDAQ:TIVC) shares rose 5.02% to $0.23. The market value of their
Gainers Windtree Therapeutics Inc (NASDAQ:WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure." ECARX Holdings Inc. (NASDAQ:ECX) gained 68% to $5.71. Terran Orbital Corporation (NYSE:LLAP) surged 52% to $2.60 after the company annonced it has been awareded a $2.4 billion contract to design, build, and deploy 300 satellites for Rivada Space Networks. Hoth Therapeutics Inc (NASDAQ:HOTH) shares rose 34.3% to $2.6613 after dropping over 9% on Tuesday. Hoth Therapeutics recently entered into a service agreement with Shareholder Intelligence Se
Gilead Sciences Inc (NASDAQ:GILD) announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment. The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations. Related: WHO Recommends Gilead's COVID-19 Therapy For Severe Disease. Two studies analyzed clinical practice information from the U.S. Premier Healthcare databases of more than 500,000 adult patients hospitalized with COVID-19. For patients with no do
Cantor Fitzgerald initiated coverage of Sorrento Therapeutics with a rating of Overweight and set a new price target of $5.00
HC Wainwright & Co. reiterated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00 from $30.00 previously
B. Riley Securities initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento's Chairman and CEO Henry Ji. Governor Thompson's appointment is effective immediately. Most recently, Thompson served as the President of the University of Wisconsin System from July 2020 through March 2022, one of the largest
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento's board of directors. Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer merchandising and healthcare diagnostic companies to Sorrento. "Sorrento continues to strengthen its already experienced board of directors," said Henry Ji, Ph.D., Chairman and Chief Executive O